|
|
Blood, 1 March 2007, Vol. 109, No. 5, pp. 2165-2173.
Prepublished online as a Blood First Edition Paper on November 2, 2006; DOI 10.1182/blood-2006-06-028092.
Previous Article | Next Article 
Submitted June 15, 2006
Accepted October 5, 2006
Rapamycin is efficacious against primary effusion
lymphoma (PEL) cell lines in vivo by inhibiting
autocrine signaling
Sang-Hoon Sin, Debasmita Roy, Ling Wang, Michelle R Staudt, Farnaz D Fakhari, Dhavalkumar D Patel, David Henry, William J Harrington, Blossom A Damania, and Dirk P Dittmer*
University of North Carolina at Chapel Hill
University of Pennsylvania
University of Miami
* Corresponding author; email: ddittmer{at}med.unc.edu.
The anti tumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears concomitant with Kaposi's sarcoma as an AIDS and Kaposi's sarcoma-associated herpesvirus (KSHV) linked neoplasm. We find that (i) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (ii) mTOR, it's activator Akt and its target p70S6 kinase are phosphorylated in PEL; (iii) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation; (iv) KSHV transcription is unaffected; (v) inhibition of IL-10 signaling correlates with drug sensitivity; and (vi) addition of exogenous IL-10 or IL-6 can reverse the rapamycin growth arrest. This validates sirolimus as a new treatment option for PEL.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. El-Salem, P. N. Raghunath, M. Marzec, X. Liu, M. Kasprzycka, E. Robertson, and M. A. Wasik
Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas
Am. J. Pathol.,
August 1, 2009;
175(2):
817 - 824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis
Clin. Cancer Res.,
February 15, 2009;
15(4):
1297 - 1307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Armand, S. Gannamaneni, H. T. Kim, C. S. Cutler, V. T. Ho, J. Koreth, E. P. Alyea, A. S. LaCasce, E. D. Jacobsen, D. C. Fisher, et al.
Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning
J. Clin. Oncol.,
December 10, 2008;
26(35):
5767 - 5774.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Gasperini, S. Sakakibara, and G. Tosato
Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis
J. Leukoc. Biol.,
October 1, 2008;
84(4):
994 - 1000.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Wang and B. Damania
Kaposi's Sarcoma-Associated Herpesvirus Confers a Survival Advantage to Endothelial Cells
Cancer Res.,
June 15, 2008;
68(12):
4640 - 4648.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|